Brought to you by 
GPC licenses NeoTherapeutics' satraplatin
05 Nov 2002
Executive Summary
GPC Biotech (cancer, immunology, infectious disease) licensed exclusive worldwide manufacturing and marketing rights to NeoTherapeutics' (in-licenses, develops anti-cancer compounds) Phase II cancer drug candidate satraplatin.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Alliance
- Includes Contract
- Includes Equity
- Intra-Biotech Deal
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
GPC licenses NeoTherapeutics' satraplatin
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice